Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Evaluation of a Desipramine Ceiling in Cocaine Abuse - 1

This study has been completed.
Friends Research Institute, Inc.
Information provided by:
National Institute on Drug Abuse (NIDA) Identifier:
First received: September 20, 1999
Last updated: August 16, 2005
Last verified: May 1994
The purpose of this study is to confirm whether a blood level ""ceiling"" exists on desipramine effect in cocaine abuse.

Condition Intervention Phase
Cocaine-Related Disorders
Substance-Related Disorders
Drug: Desipramine
Phase 2

Study Type: Interventional
Study Design: Primary Purpose: Treatment
Official Title: Evaluation of a Desipramine Ceiling in Cocaine Abuse

Resource links provided by NLM:

Further study details as provided by National Institute on Drug Abuse (NIDA):

Primary Outcome Measures:
  • Craving
  • Retention
  • Cocaine use
  • Depression
  • Anxiety
  • Mood indicators

Estimated Enrollment: 0
Study Start Date: May 1994
Estimated Study Completion Date: December 2001

Ages Eligible for Study:   18 Years to 65 Years   (Adult)
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Please contact site for information.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00000245

United States, California
Friends Research Institute
Los Angeles, California, United States, 90025
Sponsors and Collaborators
National Institute on Drug Abuse (NIDA)
Friends Research Institute, Inc.
Principal Investigator: Frank Gawin, M.D. Friends Research Institute, Inc.
  More Information Identifier: NCT00000245     History of Changes
Other Study ID Numbers: NIDA-08082-1  R01-08082-1 
Study First Received: September 20, 1999
Last Updated: August 16, 2005
Health Authority: United States: Federal Government

Additional relevant MeSH terms:
Substance-Related Disorders
Cocaine-Related Disorders
Pathologic Processes
Chemically-Induced Disorders
Mental Disorders
Anesthetics, Local
Central Nervous System Depressants
Physiological Effects of Drugs
Sensory System Agents
Peripheral Nervous System Agents
Vasoconstrictor Agents
Dopamine Uptake Inhibitors
Neurotransmitter Uptake Inhibitors
Membrane Transport Modulators
Molecular Mechanisms of Pharmacological Action
Dopamine Agents
Neurotransmitter Agents
Antidepressive Agents, Tricyclic
Antidepressive Agents
Psychotropic Drugs
Enzyme Inhibitors
Adrenergic Uptake Inhibitors
Adrenergic Agents processed this record on October 21, 2016